About Fibrate Drugs
Fibrate medicinal drugs are a kind of medicinal drug that helps to minimize ldl cholesterol and triglyceride degrees in the bloodstream. Atherosclerotic arteries are brought about with the aid of excessive quantities of ldl cholesterol and triglycerides in the blood, which block or prolong oxygenated blood float to different areas of the body. Fibrate medicines decrease blood triglyceride ranges by way of decreasing triglyceride manufacturing in the liver and boosting the tempo at which extra triglycerides are eliminated from the bloodstream. Gemfibrozil and fenofibrate are two of the most regularly prescribed fibrate medicines.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that Indians Players will contribute the maximum growth to Global Fibrate Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Teva Pharmaceutical Industries (Israel), Pfizer, Inc. (United States), Mylan N.V. (United States), Sanofi SA (France), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Sun Pharmaceutical Industries, Inc. (India) and Macleods Pharmaceuticals Limited (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Aurobindo Pharma (India), Abbott (United States) and Others.
Segmentation Overview
AMA Research has segmented the market of Global Fibrate Drugs market by Type (Gemfibrozil, Lofibrate, Fenofibric Acids and Fenofibrates) and Region.
On the basis of geography, the market of Fibrate Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End users, the sub-segment i.e. Hospitals will boost the Fibrate Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital pharmacy will boost the Fibrate Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Introduction to New Mobility Technology
Market Growth Drivers:
High prevalence of chronic disorders such as diabetes
Challenges:
Lack of availability drugs
Restraints:
High cost of drugs and Side effects may cause persons death
Opportunities:
Growth in research and development and subsequent technological advancements
Market Leaders and their expansionary development strategies
In September 2019, Medicure Inc, a cardiovascular pharmaceutical company, announced that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAG tablets, from Cadila Healthcare Ltd., India ("Zydus") for US and Canadian markets.
In November 2021, Drug firm Lupin launched generic Fenofibrate capsules, used for the treatment of high cholesterol and triglyceride levels in the blood, in the US. The company has launched generic version of Antara (Fenofibrate) capsules, in the strengths of 30 mg and 90 mg in the US, Lupin said in a regulatory filing.
Key Target Audience
Manufactures, Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.